SAB Biotherapeutics, Inc. financial data

Symbol
SABS, SABSW on Nasdaq
Location
777 W 41 St St, Suite 401, Miami Beach, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 416 % -17.1%
Debt-to-equity 31.8 % -21.1%
Return On Equity 33.4 %
Return On Assets 25.3 %
Operating Margin -1.65K % -258%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 47.6M shares +416%
Common Stock, Shares, Outstanding 47.5M shares +415%
Entity Public Float 19.5M USD -36.4%
Common Stock, Value, Issued 4.76K USD +412%
Weighted Average Number of Shares Outstanding, Basic 10.7M shares +15.1%
Weighted Average Number of Shares Outstanding, Diluted 77.9M shares +741%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 85.5K USD -98.7%
Revenue from Contract with Customer, Excluding Assessed Tax 2.78M USD -56.7%
Research and Development Expense 31.1M USD +14.7%
General and Administrative Expense 12.2M USD -53.3%
Operating Income (Loss) -43.2M USD +16.6%
Nonoperating Income (Expense) 61.9M USD +898%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -45.6M USD -67.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent 18.7M USD
Earnings Per Share, Basic -2 USD/shares +62.2%
Earnings Per Share, Diluted -3 USD/shares +51%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 29.4M USD +221%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 113M USD +248%
Property, Plant and Equipment, Net 13.1M USD -18.4%
Operating Lease, Right-of-Use Asset 2.81M USD +164%
Assets 183M USD +241%
Accounts Payable, Current 2.95M USD +128%
Employee-related Liabilities, Current 3.71M USD +11.2%
Liabilities, Current 10.8M USD +22.4%
Operating Lease, Liability, Noncurrent 2.04M USD +198%
Liabilities 18.4M USD +8.76%
Accumulated Other Comprehensive Income (Loss), Net of Tax 71.2K USD +36.6%
Retained Earnings (Accumulated Deficit) -94M USD +16.6%
Stockholders' Equity Attributable to Parent 165M USD +347%
Liabilities and Equity 183M USD +241%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.8M USD +27.5%
Net Cash Provided by (Used in) Financing Activities -174K USD +55.9%
Net Cash Provided by (Used in) Investing Activities 4.67M USD
Common Stock, Shares Authorized 800M shares 0%
Common Stock, Shares, Issued 47.5M shares +412%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.26M USD +92.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 70K USD +5.82%
Deferred Tax Assets, Valuation Allowance 27.9M USD +44.9%
Deferred Tax Assets, Gross 29.7M USD +34.6%
Operating Lease, Liability 2.87M USD +169%
Payments to Acquire Property, Plant, and Equipment 129K USD +506%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 18.8M USD
Lessee, Operating Lease, Liability, to be Paid 3.42M USD +187%
Property, Plant and Equipment, Gross 29.9M USD +0.03%
Operating Lease, Liability, Current 837K USD +118%
Lessee, Operating Lease, Liability, to be Paid, Year Two 713K USD +81.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.01M USD +123%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +25.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 546K USD +337%
Lessee, Operating Lease, Liability, to be Paid, Year Three 729K USD +740%
Deferred Tax Assets, Operating Loss Carryforwards 14.7M USD +42.9%
Preferred Stock, Shares Issued 42K shares -0.51%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 709K USD +686%
Operating Lease, Payments 868K USD -5.45%
Additional Paid in Capital 265M USD +70.5%
Preferred Stock, Shares Outstanding 42K shares -0.51%
Depreciation, Depletion and Amortization 3.1M USD -34.3%
Deferred Tax Assets, Net of Valuation Allowance 1.87M USD -34.6%
Share-based Payment Arrangement, Expense 2.72M USD -3.19%
Interest Expense 317K USD -2.75%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%